features that enable a general platform for the rational design of dual kinase-bromodomain inhibitors. Here we present data from the DiscoveRx KINOMEscan and BROMOscan platforms that demonstrate feasibility for the rational design of dual inhibitors that target new kinase-bromodomain pairs. These results suggest that the concept of dual kinase-bromodomain inhibitors can be expanded beyond PLK, JAK2, and FLT3 kinases and beyond BET family bromodomains as well.